Stock On Watch: Hamilton Edward Arthur Just Opened Huge Combimatrix Corp Position

Stock On Watch: Hamilton Edward Arthur Just Opened Huge Combimatrix Corp Position

The New Hamilton Edward Arthur Holding in Combimatrix Corp

Hamilton Edward Arthur filed with the SEC SC 13G/A form for Combimatrix Corp. The form can be accessed here: 000121465916014145. As reported in Hamilton Edward Arthur’s form, the filler as of late owns 4.59% or 109,053 shares of the Health Care–company.

Combimatrix Corp stake is a new one for the and it was filed because of activity on August 5, 2016. We feel this shows Hamilton Edward Arthur’s positive view for the stock.

Combimatrix Corp Institutional Sentiment

Latest Security and Exchange filings show 11 investors own Combimatrix Corp. The institutional ownership in Q3 2015 is low, at 254.91% of the outstanding shares. This is increased by 4465371 the total institutional shares. 6066755 were the shares owned by these institutional investors. In total 2 funds opened new Combimatrix Corp stakes, 5 increased stakes. There were 2 that closed positions and 2 reduced them.

Jim Simons Renaissance Technologies Llc is an institutional investor bullish on Combimatrix Corp, owning 41198 shares as of Q3 2015 for less than 0.01% of its portfolio. Vanguard Group Inc owns 4654046 shares or 0.01% of its portfolio. MN Perkins Capital Management Inc have 0.53% of their stock portfolio for 423938 shares. Further, Marathon Capital Management reported stake worth 0.01% of its US stock portfolio. The CA Longwood Capital Partners Llc owns 893644 shares. Combimatrix Corp is 0.58% of the manager’s US portfolio.

Business Profile

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The Company specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid-based testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping. Its prenatal and postnatal microarray focuses on diagnosing genomic syndromes associated with intellectual disability, developmental delays, congenital anomalies, dysmorphic features and autism spectrum disorders. It develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (products of conception analysis), prenatal genetics and postnatal developmental disorders.

SEC Form 13G is required when the filer owns between (5% and 20%) of a company and plans to hold it only as a passive investor. In case the filler intend to exert control and the stake’s exceeds 20%, then 13D Form must be filed. These filings can NOT be a precursor to “change of control” events such as hostile takeovers, company breakups or others.

Analysts await CombiMatrix Corp (NASDAQ:CBMX) to report earnings on November, 2. They expect $-1.07 EPS, up 45.13% or $0.88 from last year’s $-1.95 per share. After $-0.89 actual EPS reported by CombiMatrix Corp for the previous quarter, Wall Street now forecasts 20.22% negative EPS growth.

The stock closed at $2.6 during the last session. It is down 48.00% since March 16, 2016 and is downtrending. It has underperformed by 53.54% the S&P500.

CombiMatrix Corporation is a provider of molecular diagnostic solutions. The company has a market cap of $6.07 million. The Firm specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. It currently has negative earnings. It performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis, fluorescence in situ hybridization and karyotyping.

More recent CombiMatrix Corp (NASDAQ:CBMX) news were published by: Marketwatch.com which released: “CombiMatrix’s stock soars 21% premarket after distribution agreement announced” on February 24, 2011. Also Quotes.Wsj.com published the news titled: “CombiMatrix Corp. CBMX (US: Nasdaq)” on February 11, 2011. Seekingalpha.com‘s news article titled: “CombiMatrix Corporation’s (CBMX) CEO Mark McDonough Q2 2016 Results – Earnings …” with publication date: August 04, 2016 was also an interesting one.

According to Zacks Investment Research, “CombiMatrix Corporation is a diversified biotechnology business that develops proprietary technologies, including products and services in potential markets where their products and services can be utilized. The Company’s products and services are specially utilized in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology and defense and homeland security markets. The technologies they have developed include a platform technology to rapidly produce user-defined, in-situ synthesized, oligonucleotide arrays for use in identifying and determining the roles of genes, gene mutations and proteins. This technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. Other technologies include proprietary molecular synthesis and screening methods for the discovery of potential new drugs.”

CBMX Company Profile

CombiMatrix Corporation, incorporated on July 11, 2000, is a well-known provider of molecular diagnostic solutions. The Firm specializes in pre-implantation genetic screening, miscarriage analysis, prenatal diagnosis and pediatric developmental disorders, offering deoxyribonucleic acid (DNA) testing for the detection of genetic abnormalities, which cannot be identified through traditional methodologies. The Firm performs genetic testing utilizing a range of cytogenomic techniques, including chromosomal microarray analysis (CMA), fluorescence in situ hybridization (FISH) and karyotyping. The Firm also holds interests in Leuchemix, Inc., which is a drug development firm focused on developing a series of compounds to address a number of oncology-related diseases. The Firm develops and markets its molecular testing services in approximately four markets, such as in vitro fertilization (IVF), miscarriage analysis (also referred to as products of conception analysis (POC)), prenatal genetics and postnatal developmental disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment